阿立哌唑及利培酮治疗女性精神分裂症对照探究.docVIP

阿立哌唑及利培酮治疗女性精神分裂症对照探究摘 要 目的：比较阿立哌唑和利培酮治疗女性精神分裂症患者的疗效及安全性。方法：女性精神分裂症患者60例，随机分为阿立哌唑组30例和利培酮组30例，疗程12周。采用阳性与阴性症状量表（PANSS）评价疗效，治疗中采用副作用量表（TESS）及实验室检查评价安全性。结果：阿立哌唑组显效率为75%，有效率为89.29%，利培酮组分别为73.08%和92.31%，两组结果无显著差异；阿立哌唑组体质量较治疗前无显著增加，利培酮组体质量增加明显，且出现多例闭经。结论：阿立哌唑治疗女性精神分裂症疗效与利培酮相当，且较为安全。 关键词 精神分裂症 阿立哌唑 利培酮 女性 中图分类号：R971.4；R969.4 文献标识码：B 文章编号：1006-1533(2012)15-0027-03 Comparative study on aripiprazole and risperidone for treatment of female schizophrenics SUN Zhong-li, YAO Xian-hu, CHEN Jing-lan (Huaibei City Psychiatric Hospital, Huaibei 235043, China) ABSTRACT Objective: To evaluate the efficacy and safety of aripiprazole and risperidone in the treatment of female schizophrenics. Method: Sixty female schizophrenic patients were randomly divided into aripiprazole group (n=30) and risperidone group (n=30). The therapeutic period was 12 weeks. Positive and negative symptoms scale (PANSS) and the treatment emergent symptoms scale (TESS) were used to evaluate the efficacy and the safety, respectively. Result: There were no significant differences between two groups in both markedly response rate (75% vs 73.08%) and improved rate (89.29% vs 92.31%). The body weights in aripirazole group were not significantly increased after treatment, but they were in risperdone group and the menstruation was lost in part as well. Conclusion: Aripirazole is safer and has similar efficacy to risperidone in the treatment of female schizophrenic patients. KEY WORDS schizophrenia; aripirazole; risperidone; female 本研究采用阿立哌唑（商品名：奥派）与利培酮（商品名：思利舒）治疗女性精神分裂症患者，并对疗效及安全性进行比较，现报告如下。 1 对象和方法 1.1 对象 均为来自我院2009年1月至2011年4月住院的女性精神分裂症患者。符合中国精神障碍分类与诊断标准第3版诊断标准：阳性与阴性症状量表（PANSS）评分≥60分；排除：严重躯体疾病、酒或药物依赖者，妊娠、哺乳妇女。 共入组60例，随机分为两组，阿立哌唑组和利培酮组各30例。60例患者中54例完成12周治疗，脱落6例，脱落率为10%。其中阿立哌唑组脱落2例，疗效不佳合并用药和自动出院各1例；利培酮组脱落4例，疗效不佳改药1例，自动出院3例。阿立哌唑组28例，最小年龄16岁，最大年龄为55岁，平均年龄（33.25±10.05）岁，病程最短2个月，最长252个月，平均病程（57.50±49.00）个月；利培酮组26例，最小年龄18岁，最大年龄59岁，平均年龄（31.96±11.28）岁，病程最短1个月，最长110个月，平均病程（55.15±37.76）个月。 两组以上各项无显著性